Axonics Modulation Technologies, Inc. (AXNX): Price and Financial Metrics


Axonics Modulation Technologies, Inc. (AXNX): $60.39

0.49 (+0.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AXNX Stock Price Chart Interactive Chart >

Price chart for AXNX

AXNX Price/Volume Stats

Current price $60.39 52-week high $64.36
Prev. close $59.90 52-week low $32.15
Day low $59.45 Volume 524,900
Day high $60.73 Avg. volume 554,478
50-day MA $58.02 Dividend yield N/A
200-day MA $51.39 Market Cap 2.53B

Axonics Modulation Technologies, Inc. (AXNX) Company Bio


Axonics Modulation Technologies, Inc. is a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation (SNM) solutions. The company focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in 2013 and is headquartered in Irvine, CA.


AXNX Latest News Stream


Event/Time News Detail
Loading, please wait...

AXNX Latest Social Stream


Loading social stream, please wait...

View Full AXNX Social Stream

Latest AXNX News From Around the Web

Below are the latest news stories about Axonics Inc that investors may wish to consider to help them evaluate AXNX as an investment opportunity.

Axonics' implantable sacral neurostimulator gets European CE mark

Axonics (AXNX) announces European CE Mark approval of its second generation Axonics r-SNM implantable neurostimulator ((INS)) and wireless patient remote control with SmartMRI technology. Axonics previously received FDA approval for this INS and remote control during 2020. This version reduces how frequently a patient needs to recharge their sacral neuromodulation device...

Seeking Alpha | May 18, 2021

Axonics secures $175M capital via equity raise

Axonics (AXNX) has priced its public offering of 3.5M common shares at $50.00/share, for expected gross proceeds of $175M.Underwriters' over-allotment is an additional 525K shares. Net proceeds will be used to repay outstanding indebtedness, for commercialization purpose, R&D activities, working capital and general corporate purposes.Closing date is May 14.Shares down 4.6% after-hours.Previously...

Seeking Alpha | May 12, 2021

Read More 'AXNX' Stories Here

AXNX Price Returns

1-mo 11.77%
3-mo 5.01%
6-mo 37.59%
1-year 67.84%
3-year N/A
5-year N/A
YTD 20.97%
2020 80.15%
2019 83.39%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6946 seconds.